China Pharma price to free cash flow CPHI

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 492×; Jul 2026
9-year median: 10.2×
9-year range: 3.9× to 492×
Peer median: 11.4×

China Pharma's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Jul 2026, at 492×.

On the days it had one over the last 9 years, its median was 10.2×, from 3.9× in Oct 2017 to 492× in Jul 2026.

Price to free cash flow over time

median 10.2×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	492×	17.3×	492×
2025	41.4×	12.7×	54.6×
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	45.5×	7.6×	45.5×
2019	6.8×	5.5×	20.1×
2018	5.1×	5.0×	19.3×
2017	4.8×	3.9×	5.1×
2016	2.5×	1.7×	2.5×
2015	2.0×	0.6×	2.0×
2014	0.5×	0.3×	0.5×
2013	2.7×	1.7×	4.7×
2012	3.4×	3.0×	4.9×

Against its peers

Companies in Drug Manufacturers - General nearest China Pharma's size, closest first, today.

Company	Price to free cash flow
CPHIChina Pharma	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	n/m
LFVNLifevantage	11.0×
NATRNatures Sunshine Products	11.8×
Peer median	11.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on China Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.